Leader A, Hofstetter L, Spectre G (2021) Challenges and advances in managing thrombocytopenic cancer patients. J Clin Med 10:1169. https://doi.org/10.3390/jcm10061169

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stanworth SJ, Shah A (2022) How i use platelet transfusions. Blood 140:1925–1936. https://doi.org/10.1182/blood.2022016558

Article  CAS  PubMed  Google Scholar 

Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dölken G, Klenner A, Hänel M, Herbst R, Junghanss C, Ehninger G (2012) Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 380:1309–1316. https://doi.org/10.1016/S0140-6736(12)60689-8

Article  PubMed  Google Scholar 

Chen C-Y, Tai C-H, Cheng A, Wu H-C, Tsay W, Liu J-H, Chen P-Y, Huang S-Y, Yao M, Tang J-L, Tien H-F (2012) Intracranial hemorrhage in adult patients with hematological malignancies. BMC Med 10:97. https://doi.org/10.1186/1741-7015-10-97

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, Büller HR, Sørensen HT (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137:1959–1969. https://doi.org/10.1182/blood.2020007338

Article  CAS  PubMed  Google Scholar 

Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB (2008) The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 112:504–510. https://doi.org/10.1182/blood-2007-10-117051

Article  CAS  PubMed  Google Scholar 

Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464. https://doi.org/10.1001/archinte.166.4.458

Article  PubMed  Google Scholar 

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol 59:7351. https://doi.org/10.1200/JCO.2014.59.7351.

Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing G-J, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK (2021) Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160:2247–2259. https://doi.org/10.1016/j.chest.2021.07.056

Article  PubMed  Google Scholar 

Falanga A, Leader A, Ambaglio C, Bagoly Z, Castaman G, Elalamy I, Lecumberri R, Niessner A, Pabinger I, Szmit S, Trinchero A, Ten Cate H, Rocca B (2022) EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. HemaSphere 6:e750. https://doi.org/10.1097/HS9.0000000000000750

Article  PubMed  PubMed Central  Google Scholar 

Thachil J, Carrier M, Lisman T (2022) Anticoagulation in thrombocytopenic patients—time to rethink? J Thromb Haemost 20:1951–1956. https://doi.org/10.1111/jth.15789

Article  CAS  PubMed  Google Scholar 

Laporte S, Benhamou Y, Bertoletti L, Frère C, Hanon O, Couturaud F, Moustafa F, Mismetti P, Sanchez O, Mahé I (2024) INNOVTE CAT Working Group, management of cancer-associated thromboembolism in vulnerable population. Arch Cardiovasc Dis 117:45–59. https://doi.org/10.1016/j.acvd.2023.11.009

Article  PubMed  Google Scholar 

Leader A, ten Cate H, Spectre G, Beckers EAM, Falanga A (2018) Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps. Crit Rev Oncol Hematol 132:76–88. https://doi.org/10.1016/j.critrevonc.2018.09.014

Article  CAS  PubMed  Google Scholar 

Leader A, Ten Cate V, Ten Cate-Hoek A, Spectre G, Beckers E, Raanani P, Giaccherini C, Pereg D, Schouten H, Falanga A, Ten Cate H (2019) Managing anti-platelet therapy in thrombocytopaenic patients with haematological malignancy: a multinational clinical vignette-based experiment. Thromb Haemost 119:163–174. https://doi.org/10.1055/s-0038-1676520

Article  PubMed  Google Scholar 

Livneh N, Braeken D, Drozdinsky G, Gafter-Gvili A, Seelig J, Rozovski U, Berger T, Raanani P, Falanga A, Ten Cate H, Spectre G, Leader A (2021) Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy. J Thromb Thrombol 52:590–596. https://doi.org/10.1007/s11239-021-02393-8

Article  CAS  Google Scholar 

Falanga A, Ay C, Nisio MD, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K (2023) Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline☆. Ann Oncol 34:452–467. https://doi.org/10.1016/j.annonc.2022.12.014

Article  CAS  PubMed  Google Scholar 

López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P, Díez-Villanueva P, Escobar Cervantes C, Alonso Martín C, Alonso Salinas GL, Arenas M, Arrarte Esteban VI, Ayala de La Peña F, Castro Fernández A, García Pardo H, García-Sanz R, González Porras JR, López de Sá E, Lozano T, Marco Vera P, Martínez Marín V, Mesa Rubio D, Montero Á, Oristrell G, Pérez de Prado A, Velasco Del Castillo S, Virizuela Echaburu JA, Zatarain-Nicolás E, Anguita Sánchez M, Tamargo Menéndez J (2019) Expert reviewers, atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev. Espanola Cardiol. Engl. Ed 72:749–759. https://doi.org/10.1016/j.rec.2019.03.019

Article  Google Scholar 

Chalayer E, Cavalieri D, Martignoles JA, Genthon A, Tavernier E, Tardy B (2017) Antithrombotic therapy and platelet transfusions in hematologic malignancy patients presenting chemotherapy-induced thrombocytopenia: a French survey. Transfusion (Paris) 57:1717–1723. https://doi.org/10.1111/trf.14120

Article  Google Scholar 

Maier CL, Stanworth SJ, Sola-Visner M, Kor D, Mast AE, Fasano R, Josephson CD, Triulzi DJ, Nellis ME (2023) Prophylactic platelet transfusion: is there evidence of benefit, harm, or no effect? Transfus Med Rev 37:150751. https://doi.org/10.1016/j.tmrv.2023.150751

Article  PubMed  Google Scholar 

Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100. https://doi.org/10.1378/chest.10-0134

Article  PubMed  Google Scholar 

Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272. https://doi.org/10.1378/chest.09-1584

Article  PubMed  Google Scholar 

Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362:600–613. https://doi.org/10.1056/NEJMoa0904084

Article  CAS  PubMed  PubMed Central  Google Scholar 

Booth S, HaemSTAR Network M, Desborough N, Curry S. Stanworth (2022) Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort. J Thromb Haemost. JTH 20:1830–1838. https://doi.org/10.1111/jth.15748

Article  CAS  PubMed  Google Scholar 

Tardy B, Chalayer E, Kamphuisen PW, Ni Ainle F, Verhamme P, Varlet MN, Chauleur C, Rodger M, Merah A, Buchmuller A, Bistervels I, De Sancho MT, Middeldorp S, Bertoletti L (2019) SSC Subcommittee on Control of Anticoagulation of the ISTH, Definition of bleeding events in studies evaluating prophylactic antithrombotic therapy in pregnant women: a systematic review and a proposal from the ISTH SSC. J Thromb Haemost JTH 17:1979–1988. https://doi.org/10.1111/jth.14576

Article  PubMed  Google Scholar 

Carney BJ, Wang T-F, Ren S, George G, Al Homssi A, Gaddh M, Connolly GC, Shah VI, Bogue T, Bartosic A, Neuberg D, Baumann Kreuziger L, Zwicker JI, Network Investigators VENUS (2021) Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv 5:5546–5553. https://doi.org/10.1182/bloodadvances.2021005966

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S (1993) Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 153:1541–1546

Article  CAS  PubMed  Google Scholar 

Partsch H, Kechavarz B, Köhn H, Mostbeck A (1997) The effect of mobilisation of patients during treatment of thromboembolic disorders with low-molecular-weight heparin. Int Angiol J Int Union Angiol 16:189–192

CAS  Google Scholar